Author(s):
Bhagyashree Tayade, Vikram Gharge, Balasaheb Jadhav, Anant Patil, Chetan Parde, Shraddha Patil
Email(s):
Vikram.gharge@zuventus.com
DOI:
10.52711/2231-5675.2026.00007 
Address:
Bhagyashree Tayade, Vikram Gharge*, Balasaheb Jadhav, Anant Patil, Chetan Parde, Shraddha Patil
Zuventus Healthcare Limited, Plot No. P-2, SBM, Ground Floor (Part-B) and First Floor.
I.T.B.T. Park, Phase –II, MIDC, Hinjawadi, Pune – 411057, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 1,
Year - 2026
ABSTRACT:
Stability is a cornerstone of pharmaceutical product development, ensuring the safety, efficacy and longevity of drug formulations. This review explores the importance of critical and physical parameters influencing the stability of both Active Pharmaceutical Ingridients (APIs) and finished drug products. Critical factors such as temperature, humidity, light exposure, pH and their effects on chemical degradation, physical changes and overall product integrity are discussed in detail. Temperature accelerates degradation processes like hydrolysis and oxidation, while humidity can lead to hydrolysis, microbial contamination and changes in the physical form of solid dosage forms. Light exposure can cause photo-degradation, altering drug potency and pH variations affect solubility and stability. Physical parameters, including particle size, viscosity, color and clarity, also play vital roles in determining stability by influencing dissolution rates, bioavailability and uniformity. Methods for evaluating these parameters through accelerated and real-time stability testing are examined, highlighting their significance in predicting shelf life and storage conditions. Furthermore, the role of packaging in protecting against environmental factors and ensuring stability is addressed. The review also discusses regulatory guidelines for stability testing and their role in ensuring product quality. Understanding and controlling these stability factors is essential for ensuring the safety and therapeutic effectiveness of pharmaceutical products throughout their shelf life.
Cite this article:
Bhagyashree Tayade, Vikram Gharge, Balasaheb Jadhav, Anant Patil, Chetan Parde, Shraddha Patil. Critical Parameters affecting Stability of APIs and Drug Products: A Review. Asian Journal of Pharmaceutical Analysis. 2026; 16(1):41-0. doi: 10.52711/2231-5675.2026.00007
Cite(Electronic):
Bhagyashree Tayade, Vikram Gharge, Balasaheb Jadhav, Anant Patil, Chetan Parde, Shraddha Patil. Critical Parameters affecting Stability of APIs and Drug Products: A Review. Asian Journal of Pharmaceutical Analysis. 2026; 16(1):41-0. doi: 10.52711/2231-5675.2026.00007 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2026-16-1-7
13. REFERENCES:
1. Shaikh RH, Sial AA. Stability of pharmaceutical formulations. Pak. J. Pharma. Sci. 1996: 83-6.
2. Guo Y, Shalaev E, Smith S. Physical stability of pharmaceutical formulations: solid-state characterization of amorphous dispersions. TrAC Trends in Analytical Chemistry. 2013 Sep 1; 49: 137-44.
3. Huynh-Ba K. Handbook of stability testing in pharmaceutical development: regulations, methodologies, and best practices. New York: Springer; 2009.
4. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular Diversity. 2021 Aug; 25: 1315-60.
5. Kerketta GS. A crucial component of pharmaceutical quality as-surance is drug Stability Testing.
6. Chavda H. In-use stability studies: guidelines and challenges. Drug Development and Industrial Pharmacy. 2021 Sep 2; 47(9): 1373-91.
7. Rignall A. ICHQ1A (R2) Stability testing of new drug substance and product and ICHQ1C stability testing of new dosage forms. ICH Quality Guidelines: An Implementation Guide. 2017 Sep 27:3-44.
8. Ahmad B, Imran M. Emerging Organic Contaminants, Pharmaceuticals and Personal Care Products (PPCPs): A Threat to Water Quality. In Hazardous Environmental Micro-pollutants, Health Impacts and Allied Treatment Technologies 2022 Jun 28 (pp. 105-141). Cham: Springer International Publishing.
9. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. Philadelphia: Lea & Febiger; 1976.
10. Chavda H. In-use stability studies: Guidelines and Challenges. Drug Development and Industrial Pharmacy. 2021 Sep 2; 47(9):1373-91.
11. Kohn, J., & Yei, M. (2015). The effect of temperature on the stability of drug products: The Arrhenius model. Pharmaceutical Development and Technology, 20(1), 1-11
12. Taylor MJ, Weegman BP, Baicu SC, Giwa SE. New approaches to cryopreservation of cells, tissues, and organs. Transfusion Medicine and Hemotherapy. 2019 Jun 4; 46(3):197-215.
13. Macías FA, Mejías FJ, Molinillo JM. Recent advances in allelopathy for weed control: from knowledge to applications. Pest Management Science. 2019 Sep; 75(9):2413-36.
14. Guideline IH. Stability testing of new drug substances and products. Q1A (R2), Current Step. 2003 Feb; 4(1-24).
15. Chaurasia G. A review on pharmaceutical preformulation studies in formulation and development of new drug molecules. Int J Pharm Sci Res. 2016 Jun 1; 7(6):2313-20.
16. Blessy MR, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—A review. Journal of Pharmaceutical Analysis. 2014 Jun 1; 4(3):159-65.
17. Thorat P, Warad S, Solunke R, Sargar A, Bhujbal A, Shinde A. Stability study of dosage form: an innovative step. World J Pharm Pharm Sci. 2014; 3(2):1031-50.
18. Freed AL, Colgan ST, Kochling JD, Alasandro MS. Accelerating pharmaceutical development through predictive stability approaches. AAPS J. 2017; 3:2-10.
19. Thakor KA, Bhavsar DD, Thakor JR. A review article–development of forced degradation and stability indicating studies for drug substance and drug product. International Journal of Research in Pharmacology and Pharmacotherapeutics. 2016; 5(4): 291-97.
20. Rajveer B, Monika O, Agnihotri V, Arjun C, Harpalsing G. Current trend in performance of forced degradation studies for drug substance and drug products. Journal of Drug Delivery and Therapeutics. 2020; 10:149-55.
21. Narayan S, Choudhary M. A review on stability studies of pharmaceutical products. International Journal of Applied Pharmaceutical and Biological Research. 2017; 2(3):67-75.
22. Agarwal V, Sharma D. Stability testing of active pharmaceutical and scientific innovation. J Pharm Sci Innov. 2012; 1:18-23. Passi I, Salwan S, Kumar B. US-FDA approved drugs in 2020 and 2021: a review. Mini Reviews in Medicinal Chemistry. 2023 Jul 1; 23(12):1273-97.
23. Ware LB, Matthay MA. The Acute Respiratory Distress Syndrome. N Engl J Med. 2000 May 4; 342(18):1334–49.)
24. Williams III RO, Idell S. Compositions and methods for administration of an enzyme to a subject’s airway. WO2015066664 A2, 2015.
25. Stringer KA, Dunn JS, Gustafson DL. Administration of exogenous tissue plasminogen activator reduces oedema in mice lacking the tissue plasminogen activator gene. Clinical and Experimental Pharmacology and Physiology. 2004 May; 31(5‐6):327-30.
26. Stringer KA, Tobias M, Dunn JS, Campos J, Van Rheen Z, Mosharraf M, et al. Accelerated Dosing Frequency of a Pulmonary Formulation of Tissue Plasminogen Activator is Well-Tolerated in Mice. Clin Exp Pharmacol Physiol. 2008; 35(12):1454–60.).
27. Munjal M, Stodghill SP, ElSohly MA, Repka MA. Polymeric systems for amorphous Δ9-tetrahydrocannabinol produced by a hot-melt method. Part I: Chemical and thermal stability during processing. Journal of Pharmaceutical Sciences. 2006 Aug 1; 95(8):1841-53.
28. Munjal M, ElSohly MA, Repka MA. Chemical stabilization of a Δ 9-tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method: Role of Microenvironment pH. AAPs Pharmscitech. 2006 Sep; 7: E114-25.
29. Munjal M, ElSohly MA, Repka MA. Polymeric systems for amorphous Δ9-tetrahydrocannabinol produced by a hot-melt method. Part II: Effect of oxidation mechanisms and chemical interactions on stability. Journal of Pharmaceutical Sciences. 2006 Nov 1; 95(11):2473-85.
30. Franks F. Protein destabilization at low temperatures. Advances in Protein Chemistry. 1995 Jan 1; 46:105-39.
31. Hertel S, Pohl T, Friess W, Winter G. That’s cool! –Nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer. European Journal of Pharmaceutics and Biopharmaceutics. 2014 Jul 1; 87(2):357-65.
32. Bentley DL. Statistical techniques in predicting thermal stability. Journal of Pharmaceutical Sciences. 1970 Apr 1; 59(4):464-8.
33. Davies OL, Hudson HE. Stability of drugs: accelerated storage tests. Statistics in the Pharmaceutical Industry. 1981:355-95.
34. King SY, Kung MS, Fung HL. Statistical prediction of drug stability based on nonlinear parameter estimation. Journal of Pharmaceutical Sciences. 1984 May 1; 73(5):657-62.
35. Yoshioka S, Stella VJ. Stability of drugs and dosage forms. Springer Science & Business Media; 2000 Dec 31.
36. Ellin RI, Wills JH. Oximes Antagonistic to Inhibitors of Cholinesterase: Part I. Journal of Pharmaceutical Sciences. 1964 Sep 1; 53(9):995-1007.
37. Deshpande AD, Baheti KG, Chatterjee NR. Degradation of β-lactam antibiotics. Current Science. 2004 Dec 25:1684-95.
38. Hengsawas S. Importance of Stability of Pharmaceutical Formulations (Doctoral Dissertation).
39. Marsac PJ, Rumondor AC, Nivens DE, Kestur US, Stanciu L, Taylor LS. Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly (vinyl pyrrolidone). Journal of Pharmaceutical Sciences. 2010 Jan 1; 99(1):169-85.
40. Harmon P, Boccardi G. Oxidative susceptibility testing. In Pharmaceutical Stress Testing 2016 Apr 19 (pp. 180-203). CRC Press.
41. Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, Tsuda Y. The role of degradant profiling in active pharmaceutical ingredients and drug products. Advanced Drug Delivery Reviews. 2007 Jan 10; 59(1): 29-37.
42. Camacho W, Karlsson S. Assessment of thermal and thermo-oxidative stability of multi-extruded recycled PP, HDPE and a blend thereof. Polymer Degradation and Stability. 2002 Jan 1; 78(2):385-91.
43. Bruce CD. Recrystallization of guaifenesin from hot-melt extrudates containing Acryl-EZE or Eudragit L100-55. The University of Texas at Austin; 2008.
44. Kommanaboyina B. Regulation of Stability of Marketed Pharmaceuticals.
45. Anderson JR. The adaptive nature of human categorization. Psychological Review. 1991 Jul; 98(3):409.
46. Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. Journal of Applied Pharmaceutical Science. 2012 Mar 30(Issue):129-38.
47. Carstensen JT. Drug Stability: Principles and Practices. (No Title). 1995 Jan.
48. Bakshi M, Singh S. Development of validated stability-indicating assay methods—critical review. Journal of pharmaceutical and biomedical analysis. 2002 Jun 15; 28(6):1011-40.
49. Ali J, Khar RK, Ahuja A. Dosage Form and Design. CBS Publishers and Distributers. Delhi. 2008; 1:2004-05.
50. Clapham D. Stability Testing: Photostability Testing of New Drug Substances and Products ICH Q1B. ICH Quality Guidelines: An Implementation Guide. 2017 Sep 27:45-72.
51. Khan H, Ali M, Ahuja A, Ali J. Stability testing of pharmaceutical products-comparison of stability testing guidelines. Current Pharmaceutical Analysis. 2010 May 1; 6(2):142-50.
52. ICH T. Guidance for industry: Q2B validation of analytical procedures: Methodology. Food and Drug Administration, Centre for Drug Evaluation and Research, Centre for Biologics Evaluation and Research. 1996; 1269.
53. Guideline IH. Impurities in new drug substances Q3A (R2). In Proceedings of the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use, Geneva, Switzerland 2006 Oct 25 (Vol. 25).
54. Guideline IH. Impurities in New Drug Products. Q3B (R2), Current Step. 2006 Jun; 4:1-5.
55. Guideline IH. Evaluation for Stability Data. ICH Q1E. ICH. 2003 Feb; 6:1-9.
56. Iram F, Iram H, Iqbal AZ, Husain A. Forced degradation studies. Journal of Analytical & Pharmaceutical Research. 2016; 3(6):73.
57. Committee for Medicinal Products for Human Use. Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials. London, UK: European Medicines Agency. 2012.
58. Committee for Medicinal Products for Human Use. European Medicines Agency (2006). Guideline on the Limits of Genotoxic impurities. EMEA/CHMP/QWP/251344; 2006.
59. Guideline IH. Photostability testing of new drug substance and products. Fed. Register. 1996; 62:27115-22.
60. Nunes JC, Cristóvão RO, Freire MG, Santos-Ebinuma VC, Faria JL, Silva CG, Tavares AP. Recent strategies and applications for L-asparaginase confinement. Molecules. 2020 Dec 10; 25(24):5827.
61. Croxall MP, Lawrence RT, Goh MC. 1H NMR as a quick screen for photocatalytic reaction efficiency. Journal of Photochemistry and Photobiology A: Chemistry. 2019 Sep 1; 382:111965.